Dabrafenib is a kinase inhibitor used for treating patients with unresectable or metastatic melanoma, metastatic non‐small cell lung cancer, locally advanced or metastatic anaplastic thyroid cancer, pediatric low‐grade glioma, and other solid tumors harboring specific BRAF mutations [35]. This evidence concerns the gene BRAF and glioma.